{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-004698","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.561912+00:00","generated_at":"2026-06-17T14:51:34.064821+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Aclaris extends former CFO Frank Ruffo's consulting term to June 30, 2023 with $12,500 monthly fee","bullets":["Consulting term extended from March 3, 2023 through June 30, 2023.","Monthly consulting fee set at $12,500 for services rendered during the term.","No outstanding equity awards will vest after March 2, 2023; vesting ceased on that date."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-004698","json":"https://secwatch.observer/filing/0001558370-23-004698.json","markdown":"https://secwatch.observer/filing/0001558370-23-004698.md","text":"https://secwatch.observer/filing/0001558370-23-004698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023004698/0001558370-23-004698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023004698/acrs-20230323x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:51:34.064821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}